查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950434

血型鑑定試劑市場依產品類型、技術、樣本類型和最終用戶分類，全球預測（2026-2032年）

Blood Typing Reagent Market by Product Type, Technology, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血型鑑定試劑市場價值將達到 20.2 億美元，到 2026 年將成長至 22.1 億美元，到 2032 年將達到 41.5 億美元，年複合成長率為 10.83%。

關鍵市場統計數據
基準年 2025 20.2億美元
預計年份：2026年 22.1億美元
預測年份 2032 41.5億美元
複合年成長率 (%) 10.83%

對目前血型鑑定試劑狀況的簡要概述，涵蓋技術趨勢、供應狀況和營運重點，為近期採購和研發決策提供資訊。

以下執行摘要概括了塑造現代血型鑑定試劑環境的關鍵背景、策略轉折點和營運影響。它從實踐觀點概述了當前形勢，旨在為採購、開發和臨床應用方面的決策提供支援。讀者將獲得關於技術趨勢、下游終端使用者需求、供應動態和競爭格局的簡明分析，從而為即時的戰術性選擇和長期策略規劃提供基礎。

抗體工程、診斷平台和監管要求的創新如何重塑檢查室工作流程、供應商夥伴關係和品質投資

血型鑑定試劑的市場格局正經歷多重變革，這些變革正在改變檢查室的工作流程和供應鏈關係。抗體工程和重組技術的進步正在重塑試劑的一致性和批間重複性，隨著這些能力的擴展，它們正在影響血庫、診斷檢查室、醫院和研究實驗室的選擇偏好。同時，診斷技術正從傳統的手工凝集方法發展到整合流式細胞技術、微陣列和酶聯免疫吸附檢測法的平台，從而為更高通量和更豐富的數據採集創造了機會。

美國近期對試劑採購、供應連續性和籌資策略的關稅累積影響，進一步凸顯了多角化和在地採購的必要性。

美國近期關稅政策的變化正在產生一系列累積效應，這些效應波及試劑採購、供應鏈韌性和成本管理策略。進口關稅及相關貿易措施促使許多採購團隊重新評估其供應商佈局，並尋求建立多供應商結構以降低單一供應商風險。這種重新評估促使各組織盡可能優先選擇本地供應商，加快對替代供應商的資質認證流程，並加強庫存管理以減少交貨中斷。

從產品、技術、最終用戶和樣品類型等維度進行詳細的細分分析，揭示了每個群體在檢驗、相容性和採購方面的差異。

詳細的市場細分分析揭示了每種產品類型、技術、最終用戶和樣品基質的不同購買促進因素和檢驗要求。在產品類型方面，市場由凝集素、單株抗體、多株抗體和重組抗體組成。單株抗體進一步分為融合瘤來源和重組形式，而多株抗體通常來自山羊或兔子。這些物質差異會影響批次穩定性、特異性光譜以及實驗室必須管理的下游檢驗途徑。

檢驗法規結構、實驗室成熟度和分銷策略在關鍵區域對採購、檢驗和支援模式的影響

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的需求模式、監管路徑和籌資策略。在美洲，採購決策往往優先考慮快速反應、綜合技術支援以及與區域監管指南的一致性。這促使試劑供應商與大型醫院網路和血液服務提供者之間建立更緊密的夥伴關係，以確保及時交貨和協調一致的檢驗計劃。

競爭格局概述重點闡述檢驗的嚴格性、生產控制和綜合支援計畫如何為試劑供應商提供永續的競爭優勢

血型鑑定試劑市場的競爭動態呈現出多元化的態勢，既有成熟的製造商，也有專注於試劑一致性、整合解決方案和服務品質的創新參與企業。現有企業通常擁有成熟的產品系列和廣泛的分銷網路，並利用與血庫和醫院系統建立的長期合作關係。同時，新參與企業則著重於重組抗體平台、先進的品管以及能夠簡化批次追蹤和資料整合的數位化工具。

透過試劑工程和自動化，為領導企業提供提高供應鏈韌性、加快檢驗流程和降低營運風險的實用策略

產業領導者應採取一系列協調一致的行動，平衡供應鏈韌性、監管準備和技術差異化，以保障臨床工作的連續性並創造未來機會。首先，應優先考慮供應商多元化和合格框架，以便在保持臨床檢驗完整性的同時，快速引入替代製造商。建立預先核准的供應商層級和標準化的驗收測試通訊協定，有助於在物流或貿易波動影響首選供應商時，減輕由此造成的干擾。

採用透明的混合方法，結合實務工作者訪談、技術評述和比較分析，得出可操作且可複製的研究結果。

本調查方法結合了結構化的初步研究、有針對性的二次研究以及嚴謹的分析綜合，以確保獲得可靠且可操作的洞見。初步數據透過與血庫、診斷檢查室、醫院檢查室和研究機構的專家進行訪談和討論收集，以獲得關於檢驗方法、採購標準和運營限制的第一手資訊。這些專家見解與產品文件、技術白皮書和監管指南進行交叉核對，以檢驗各類試劑的性能特徵和品質預期。

本文簡明扼要地總結了檢查室和供應商在實現更穩健、更可重複的試劑操作方面應關注的策略重點和營運要務。

總之，受抗體工程技術的進步、診斷平台的不斷發展以及監管要求的日益嚴格等因素驅動，血型鑑定試劑領域正處於一個轉折點。這些因素正推動試劑形式和供應商關係轉向更注重可重複性、文件記錄和整合支援的模式。積極拓展供應商、強化檢驗框架並投資於數位化追溯的檢查室和採購團隊，將能夠更好地管理營運風險並維持臨床工作的連續性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型分類的血型鑑定試劑市場

  • 凝集素
  • 單株抗體
    • 融合瘤衍生
    • 重組
  • 多株抗體
    • 山羊
    • 兔子
  • 重組抗體

第9章 依技術分類的血型鑑定試劑市場

  • 凝血法
    • 直接團聚法
    • 間接團聚法
  • 酵素免疫分析法
  • 流式細胞技術
    • 螢光鹼
    • 基於影像
  • 微陣列

第10章 依檢體類型分類的血型鑑定試劑市場

  • 巴菲外套
  • 電漿
  • 血清
  • 全血

第11章 以最終用戶分類的血型鑑定試劑市場

  • 血庫
  • 診斷檢查室
  • 醫院
  • 研究所

第12章 血型鑑定試劑市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 血型鑑定試劑市場（依血型分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國血型鑑定試劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國血型鑑定試劑市場

第16章 中國血型鑑定試劑市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • ARKRAY, Inc.
  • Atlas Medical GmbH
  • BAG Diagnostics GmbH
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Essange Reagents
  • F. Hoffmann-La Roche Ltd
  • Grifols, SA
  • Immucor, Inc.
  • Lorne Laboratories Limited
  • Merck KGaA
  • Meril Life Sciences Pvt. Ltd.
  • Ortho Clinical Diagnostics Inc.
  • Prestige Diagnostics
  • QuidelOrtho Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Torax Biosciences Limited
  • Tulip Diagnostics（P）Ltd.
Product Code: MRR-4F7A6D4FD860

The Blood Typing Reagent Market was valued at USD 2.02 billion in 2025 and is projected to grow to USD 2.21 billion in 2026, with a CAGR of 10.83%, reaching USD 4.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.02 billion
Estimated Year [2026] USD 2.21 billion
Forecast Year [2032] USD 4.15 billion
CAGR (%) 10.83%

A concise orientation to the blood typing reagent landscape that frames technology, supply dynamics, and operational priorities to inform immediate procurement and R&D decisions

The following executive summary synthesizes the essential context, strategic inflections, and operational implications shaping the contemporary blood typing reagent environment. It frames the current landscape through a practical lens that supports decisions across procurement, development, and clinical deployment. Readers will find concise analysis of technology trends, downstream end-user requirements, supply dynamics, and competitive positioning to aid immediate tactical choices as well as longer-term strategic planning.

This introduction highlights the convergence of advanced antibody engineering, automation in identification workflows, and evolving regulatory scrutiny that together redefine how laboratories and blood banks secure reagent reliability and reproducibility. As a result, stakeholders must reconcile legacy practices with an accelerating cadence of technological alternatives and materials sourcing options. The narrative that follows prioritizes clarity, actionable insight, and an evidence-backed view of how these forces interact in real-world settings, providing a foundation for the deeper sections that examine segmentation, regional dynamics, tariff impacts, and recommended actions.

How innovations in antibody engineering, diagnostic platforms, and regulatory expectations are reshaping laboratory workflows, supplier partnerships, and quality investments

The landscape for blood typing reagents is experiencing several transformative shifts that alter both laboratory workflows and supply chain relationships. Advances in antibody engineering and recombinant approaches are reshaping reagent consistency and batch-to-batch reproducibility, and as these capabilities scale, they influence preferences across blood banks, diagnostic laboratories, hospitals, and research institutions. Concurrently, diagnostic technologies are moving beyond classic manual agglutination to integrated platforms that combine flow cytometry, microarray, and enzyme-linked assays, creating opportunities for higher throughput and richer data capture.

Parallel to technological evolution, regulatory agencies are intensifying scrutiny on reagent validation, traceability, and clinical performance documentation. This increased oversight drives greater investment in quality systems and in suppliers that can demonstrate robust manufacturing controls. At the same time, end users demand more integrated solutions that reduce hands-on time and improve result consistency, prompting vendors to bundle reagents with software and automated hardware. Collectively, these shifts are increasing the strategic importance of supplier partnerships, diversification of sourcing strategies, and investment in in-house technical capabilities to validate new reagent formats and platforms.

The cumulative effects of recent United States tariff measures on reagent sourcing, supply continuity, and procurement strategies that reinforce diversification and localization imperatives

Recent tariff policy developments in the United States have created a set of cumulative impacts that reverberate through reagent sourcing, supply chain resilience, and cost-management strategies. Import duties and related trade measures have prompted many procurement teams to reassess supplier footprints and to seek multi-sourced arrangements that reduce single-point exposure. This reassessment has led organizations to prioritize nearer-shore suppliers when possible, accelerate qualification timelines for alternative vendors, and expand inventory governance to mitigate delivery interruptions.

In response, some manufacturers have adjusted their production strategies, evolving toward localized manufacturing or strategic distribution partnerships to preserve market access and service levels. These shifts can lengthen lead times for qualification but improve longer-term stability. Diagnostics developers and clinical laboratories have also responded by intensifying supplier performance metrics, requiring more detailed batch documentation and enforcing stricter acceptance testing upon receipt. Additionally, procurement teams increasingly incorporate total landed cost considerations and contractual terms that address tariff variability and shared risk, while regulatory teams keep a close watch on documentation continuity where supplier changes intersect with product registration or clinical validation obligations.

Detailed segmentation analysis across product, technology, end user, and sample type axes that highlights validation, compatibility, and procurement differentiators for each cohort

A granular view of segmentation reveals distinct purchase drivers and validation requirements across product types, technologies, end users, and sample matrices. Within product type, the market encompasses lectins, monoclonal antibodies, polyclonal antibodies, and recombinant antibodies; monoclonal antibodies further differentiate into hybridoma-derived and recombinant formats, and polyclonal antibodies typically originate from goat or rabbit hosts. These material distinctions influence lot stability, specificity profiles, and downstream validation pathways that laboratories must manage.

Examining diagnostic modalities, the technology spectrum includes agglutination, enzyme-linked immunosorbent assays, flow cytometry, and microarray platforms; agglutination itself divides into direct and indirect approaches, while flow cytometry manifests through fluorescence-based and image-based implementations. Each technological class imposes unique performance expectations, instrumentation compatibility needs, and operator skill requirements, thereby affecting purchasing criteria and training investments.

End users show differentiated priorities: blood banks concentrate on throughput, compatibility assurance, and regulatory traceability; diagnostic laboratories emphasize analytical sensitivity, reproducibility, and integration with laboratory information systems; hospitals balance turnaround times and on-site support; and research institutions prioritize experimental flexibility and reagent provenance. Finally, sample type matters significantly, with buffy coat, plasma, serum, and whole blood presenting distinct handling constraints, anticoagulant considerations, and pre-analytical workflows. Understanding how these segmentation layers intersect enables more precise product positioning, validation roadmaps, and service models tailored to each user cohort.

An examination of how regional regulatory frameworks, laboratory maturity, and distribution strategies across major geographies affect sourcing, validation, and support models

Regional dynamics influence demand patterns, regulatory pathways, and sourcing strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, procurement decisions often prioritize responsiveness, integrated technical support, and alignment with regional regulatory guidance. This has encouraged the development of closer partnerships between reagent suppliers and large hospital networks and blood services to ensure timely deliveries and coordinated validation programs.

Across Europe, Middle East & Africa, regulatory harmonization efforts and diverse payer environments shape procurement practices, driving emphasis on compliance documentation, CE marking or equivalent pathways, and flexible distribution models that accommodate variable market access requirements. Strategic distribution agreements and regional manufacturing sites can facilitate faster response times and tailored regulatory support. In the Asia-Pacific region, a broad spectrum of laboratory maturity-from advanced centralized testing centers to decentralized hospital labs-creates parallel demand for both high-throughput automated platforms and cost-efficient, robust manual reagents. Consequently, suppliers often adopt dual strategies that combine premium product lines for reference centers with resilient, lower-complexity offerings for decentralized settings.

These regional distinctions affect supplier selection, validation timelines, and after-sales support structures. They also inform decisions about local partnerships, inventory strategies, and training programs required to ensure consistent reagent performance in diverse clinical contexts.

A competitive landscape overview emphasizing how validation rigor, manufacturing controls, and integrated support programs create durable advantages for reagent suppliers

Competitive dynamics in the blood typing reagent space reflect a mix of legacy manufacturers, specialty reagent developers, and innovative entrants that prioritize reagent consistency, integrated solutions, and service excellence. Established producers often leverage long-standing relationships with blood banks and hospital systems, offering proven product portfolios and broad distribution reach. Meanwhile, newer entrants emphasize recombinant antibody platforms, advanced quality controls, and digital tools that simplify lot tracking and data integration.

Across the supplier landscape, differentiation frequently arises from the ability to provide robust technical documentation, reliable batch-to-batch performance, and responsive technical support. Firms that invest in scalable manufacturing controls and transparent validation data tend to earn trust among diagnostic laboratories and hospital procurement teams. In addition, vendors that offer programmatic support for qualification-such as protocol templates, on-site training, and digital traceability-improve adoption rates and deepen customer relationships. Partnerships between reagent manufacturers and instrument vendors are also notable, as those alliances facilitate bundled solutions that reduce validation burdens and accelerate laboratory workflow integration.

Actionable strategies for leaders to strengthen supply resilience, accelerate validation, and capitalize on reagent engineering and automation to reduce operational risk

Industry leaders should pursue a coordinated set of actions that balance supply resilience, regulatory readiness, and technological differentiation to protect clinical continuity and unlock future opportunities. First, prioritize supplier diversification and qualification frameworks that allow rapid onboarding of alternative manufacturers while preserving clinical validation integrity. Establishing pre-approved vendor tiers and standardized acceptance testing protocols helps reduce disruption when logistics or trade measures impact preferred suppliers.

Second, invest in reagent provenance and digital traceability systems that link lot information to quality records, operator training logs, and instrument configurations. Such investments improve audit readiness and facilitate faster root-cause analysis when deviations occur. Third, accelerate adoption of recombinant and engineered antibody formats where appropriate, as these products can reduce variability and ease long-term supply planning. Simultaneously, partner closely with instrument providers to develop validated reagent-instrument packages that reduce laboratory validation workloads.

Finally, implement contractual terms that address tariff exposure, delivery windows, and shared risk arrangements with suppliers, while reinforcing robust inventory governance to balance stockholding costs against service level requirements. These measures collectively enhance operational resilience, reduce total validation overhead, and position organizations to respond quickly to technological and regulatory shifts.

A transparent mixed-methods approach combining practitioner interviews, technical review, and comparative synthesis to produce actionable and reproducible insights

The research methodology combines structured primary engagements, targeted secondary review, and rigorous analytical synthesis to ensure robust, actionable findings. Primary inputs were collected through interviews and discussions with practitioners across blood banks, diagnostic laboratories, hospital laboratories, and research institutions to capture firsthand perspectives on validation practices, procurement criteria, and operational constraints. These practitioner insights were triangulated with product documentation, technical white papers, and regulatory guidance to validate performance attributes and quality expectations across reagent classes.

Secondary analysis involved systematic review of technical literature, regulatory communications, and supplier manufacturing specifications to map the relationships between reagent type, technology platform, and end-user requirements. The synthesis stage applied comparative analysis to identify recurring adoption drivers, supplier differentiators, and regional nuances, while careful attention to methodological transparency ensured reproducibility of findings. Throughout, the approach emphasized practical relevance by focusing on operational implications rather than purely theoretical assessments, supporting decision-makers with clear, implementable recommendations grounded in empirical evidence.

A concise synthesis of strategic priorities and operational imperatives that guide laboratories and suppliers toward more resilient, reproducible reagent practices

In conclusion, the blood typing reagent domain is at an inflection point driven by advances in antibody engineering, evolving diagnostic platforms, and heightened regulatory expectations. These forces encourage a shift toward reagent formats and supplier relationships that prioritize reproducibility, documentation, and integrated support. Laboratories and procurement teams that proactively diversify suppliers, strengthen validation frameworks, and invest in digital traceability will better manage operational risk and preserve clinical continuity.

Moreover, regional realities and tariff dynamics require tailored strategies that reconcile local regulatory requirements with resilience-focused procurement policies. By aligning product selection with end-user workflows and sample-type constraints, organizations can reduce validation burdens and improve diagnostic reliability. The recommendations provided herein offer a strategic roadmap for navigating current pressures while positioning organizations to take advantage of technological improvements and supplier innovations that enhance performance and reduce variability over time.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Typing Reagent Market, by Product Type

  • 8.1. Lectin
  • 8.2. Monoclonal Antibody
    • 8.2.1. Hybridoma Derived
    • 8.2.2. Recombinant
  • 8.3. Polyclonal Antibody
    • 8.3.1. Goat
    • 8.3.2. Rabbit
  • 8.4. Recombinant Antibody

9. Blood Typing Reagent Market, by Technology

  • 9.1. Agglutination
    • 9.1.1. Direct Agglutination
    • 9.1.2. Indirect Agglutination
  • 9.2. Enzyme Linked Immunosorbent Assay
  • 9.3. Flow Cytometry
    • 9.3.1. Fluorescence Based
    • 9.3.2. Image Based
  • 9.4. Microarray

10. Blood Typing Reagent Market, by Sample Type

  • 10.1. Buffy Coat
  • 10.2. Plasma
  • 10.3. Serum
  • 10.4. Whole Blood

11. Blood Typing Reagent Market, by End User

  • 11.1. Blood Banks
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutions

12. Blood Typing Reagent Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood Typing Reagent Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood Typing Reagent Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Blood Typing Reagent Market

16. China Blood Typing Reagent Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. ARKRAY, Inc.
  • 17.7. Atlas Medical GmbH
  • 17.8. BAG Diagnostics GmbH
  • 17.9. Becton, Dickinson and Company
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. Danaher Corporation
  • 17.12. Essange Reagents
  • 17.13. F. Hoffmann-La Roche Ltd
  • 17.14. Grifols, S.A.
  • 17.15. Immucor, Inc.
  • 17.16. Lorne Laboratories Limited
  • 17.17. Merck KGaA
  • 17.18. Meril Life Sciences Pvt. Ltd.
  • 17.19. Ortho Clinical Diagnostics Inc.
  • 17.20. Prestige Diagnostics
  • 17.21. QuidelOrtho Corporation
  • 17.22. Siemens Healthineers AG
  • 17.23. Thermo Fisher Scientific Inc.
  • 17.24. Torax Biosciences Limited
  • 17.25. Tulip Diagnostics (P) Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD TYPING REAGENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD TYPING REAGENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY LECTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY LECTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY LECTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HYBRIDOMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HYBRIDOMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HYBRIDOMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY GOAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY GOAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY GOAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RABBIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RABBIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RABBIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RECOMBINANT ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIRECT AGGLUTINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIRECT AGGLUTINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIRECT AGGLUTINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY INDIRECT AGGLUTINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY INDIRECT AGGLUTINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY INDIRECT AGGLUTINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLUORESCENCE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLUORESCENCE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY FLUORESCENCE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY IMAGE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY IMAGE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY IMAGE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BUFFY COAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BUFFY COAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BUFFY COAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GCC BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 168. GCC BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 195. G7 BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. G7 BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. NATO BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 204. NATO BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. NATO BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL BLOOD TYPING REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA BLOOD TYPING REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY POLYCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY AGGLUTINATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA BLOOD TYPING REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)